Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back

Revance Therapeutics to Participate in the 27th Annual Piper Jaffray Healthcare Conference

November 19, 2015

NEWARK, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today the Company plans to participate in the 27th Annual Piper Jaffray Healthcare Conference in New York, NY.

Revance management is scheduled for a fireside chat on Tuesday, December 1, 2015 at 3:00pm ET. Interested parties can access the live audio webcast at http://investors.revance.com/index.cfm. An archived audio replay will be available on the website for 30 days.

About Revance Therapeutics, Inc.
Revance is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented TransMTS® peptide delivery system to address unmet needs in the large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin A through two novel drug product candidates, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a targeted and potentially long-lasting delivery. Revance is pursuing clinical development for drug product candidates RT001 topical and RT002 injectable in a broad spectrum of aesthetic and therapeutic indications. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. More information on Revance Therapeutics can be found at www.revance.com.

"Revance Therapeutics," TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

CONTACT: Investors:

         Revance TherapeuticsJeanie Herbert

         (714) 325-3584

         jherbert@revance.com



         Westwicke PartnersLeigh Salvo

         (415) 513-1281

         leigh.salvo@westwicke.com



         Trade Media:

         Nadine Tosk

         (847) 920-9858

         nadinepr@gmail.com
Source: Revance Therapeutics, Inc.

News Provided by Acquire Media